- Home
- About
- About NephU
- Meet The Team
- Supporting Organizations
- Community Advisors
- Contact Us
- Diversity, Equity, & Inclusion
- IgAN
- Expert Insights
- Mechanism of Disease
- Disease Burden & Progression
- Disease Management
- HCP/Patient Dialogue
- Events
- Resource Center
- Rare Kidney Diseases (PKD, IgAN, & Others)
- Kidney Disease & Mental Health
- Kidney Disease & Comorbid Conditions
- Transplantation & Dialysis
- NephU Nutrition & The NephChefR
- Radiology Toolkit
- On Demand Webinars
- Infographics
- Podcasts
- Videos
- Request a Presentation
- Simulators
What interests you?+Help Us Enhance Your NephU ExperienceHelp Us Enhance Your NephU Experience
User experience form
Archives

4 Part IgAN Experience
About This Event
4 Part IgAN Experience
An innovative, four-part educational experience designed to immerse healthcare professionals in the evolving landscape of IgA Nephropathy (IgAN) through interactive technology, evidence-based literature, real-world case studies, and high-impact educational tools.
Program Overview
Participants will engage in a dynamic dinner event that blends interactive learning with case-based discussions. The program is modular, allowing requesters to select their preferred literature topic and patient case focus, while the other elements remain consistent and highly engaging.B-Cell Biology and the Role of Cytokines in B-Cell Modulation
The physiological function of APRIL in B-cell regulation, and the growing body of evidence supporting APRIL inhibition as a potential therapeutic approach.Literature Review (Journal Club Style)
- RaDaR Study: Long-term outcomes in IgAN and the predictive value of proteinuria and eGFR decline
Apple Vision Pro Immersive Experience
Experience disease-state education like never before. Using Apple Vision Pro technology, participants can visually explore:- The 4-hit pathogenic process of IgAN
- The role of APRIL in initiating and sustaining kidney injury in IgAN
NephU Resource Station
Hands-on review of pre-approved NephU materials tailored to IgAN, including:
- Interactive simulators
- Infographics
- Educational tools and treatment summaries
Patient Case Study Review
Dive into a real-world case panel discussion on : Persistent Proteinuria in patients previously considered low riskLocation
UCLA Meyer & Renee Luskin Conference Center
425 Westwood Plaza
Los Angeles, California 90095 United States + Google Map(855) 522-8252 View Venue WebsiteFeaturing
Marla Dallal, PharmD, RPH
Nephrology Senior Medical Science LiaisonOtsuka Pharmaceutical Development & Commercialization, Inc.*Marla Dallal, PharmD, RPH is a Medical Science Liaison at Otsuka Pharmaceutical Development and Commercialization covering Southern California. She earned her Doctor of Pharmacy degree from the University of Southern California, School of Pharmacy in Los Angeles. While in pharmacy school, Dr Dallal pursued various clinical internships within the acute care and ambulatory care settings at Cedars-Sinai Medical Center and Kaiser Permanente. Prior to joining Otsuka, Dr Dallal held various positions within Medical Affairs at Amgen Inc covering the cardiometabolic and nephrology therapeutic areas. She also served as a preceptor at Amgen Inc, where she instructed pharmacy students on Advanced Pharmacy Practice rotations. She is currently licensed as a pharmacist in the state of California with the National Association Board of Pharmacy.
Addis Alemayehu, PharmD
Senior Regional Medical Lead
Lama Abdelnour
Assistant Clinical Professor of Medicine, Medical Director – Living Donor Kidney Transplant Program in Westwood.Dr. Lama Abdelnour is an Assistant Clinical Professor of Medicine and the Medical Director of the Living Donor Kidney Transplant Program in Westwood. Board-certified inand Internal Medicine, she completed her internal medicine training at the University of Nevada School of Medicine in Las Vegas and her nephrology fellowship at the Keck School of Medicine of USC.
Dr. Abdelnour specializes in general nephrology, with a particular focus on glomerular diseases, including IgA nephropathy, Focal Segmental Glomerulosclerosis (FSGS), membranous nephropathy, minimal change disease, Lupus Nephritis, and ANCA vasculitis. She is also dedicated to optimizing the health and evaluation of living kidney donors.
Beyond her clinical practice, Dr. Abdelnour is a principal investigator on multiple research projects, contributing to advancements in glomerular diseases and living kidney donation.
Mohammad Kamgar
Marla Dallal, PharmD, RPH and Addis Alemayehu, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Registration
Join Today for Instant Access to all NephU Offerings.
Membership is free!
Join NephU today at no cost to register for this event and access to other premium content.
- The NephU Community is collaborating to improve care and the future outcomes for individuals with kidney disease and other related conditions.
- Quickly learn more about the topics that interest you.
- Access our library of on-demand kidney health resources
- Gain key insights from industry experts & though leaders.
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the kidney health community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2025 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved.